Orforglipron (LY-3502970)
Oral Small-Molecule GLP-1 Receptor Agonist | Weight Loss & Diabetes
Community Research
Join others researching Orforglipron — share findings, ask questions, and learn from real experiences
First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.
Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life.
Molecular Data
Not applicable - synthetic small molecule Complex or non-standard sequence format
Research Indications
ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss.
ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss.
Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%).
91% achieved near-normal blood sugar levels versus 42% with placebo.
ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%.
Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.
Dosing Protocols
Once-daily oral tablet requiring no reconstitution. Can be taken with or without food or water at any time of day.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Type 2 diabetes initiation | 3mg daily | Once daily, any time | Oral tablet |
| Type 2 diabetes moderate control | 12mg daily | Once daily, any time | Oral tablet |
| Type 2 diabetes optimal control | 36mg daily | Once daily, any time | Oral tablet |
| Weight loss initiation | 6mg daily | Once daily, any time | Oral tablet |
| Weight loss optimization | 36mg daily | Once daily, any time | Oral tablet |
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Diarrhea (more prevalent than with injectable GLP-1s)
- Nausea (typically improves after first month)
- Appetite reduction
Stop Signs - Discontinue if:
- Severe or persistent abdominal pain radiating to back (potential pancreatitis)
- Neck lumps, hoarseness, difficulty swallowing, or neck swelling
- Severe nausea/vomiting preventing adequate nutrition or hydration
- Signs of severe hypoglycemia (confusion, sweating, rapid heartbeat)
- Suicidal thoughts, severe depression, or significant mood changes
- Vision changes or persistent eye pain
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Pregnancy and breastfeeding
Quality Checklist
Good Signs
- Intact tablet packaging with proper labeling, batch numbers, and expiration dates
- Uniform tablet appearance without discoloration, chipping, or cracking
- Proper storage at room temperature (15-30°C)
Warning Signs
- As of late 2025, orforglipron remains investigational only; any product claiming FDA approval is fraudulent
Bad Signs
- Discolored, crumbling, or damaged tablets indicate improper storage
- Moisture exposure or humidity damage
Frequently Asked Questions
How does orforglipron compare to semaglutide for weight loss?
Orforglipron achieved 12.4% weight loss vs semaglutide's 15-20% in trials, but orforglipron is an oral tablet while semaglutide requires weekly injections. For many people, the convenience of taking a daily pill outweighs slightly lower weight loss numbers. It's still in Phase 3 trials (not yet FDA-approved), while semaglutide is established.
Why does orforglipron cause more diarrhea than other GLP-1s?
The file specifically notes that diarrhea is more prevalent with orforglipron than with injectable GLP-1s. This is likely due to its oral bioavailability and how the small molecule formulation affects the GI tract differently than peptide injections. Diarrhea typically improves after the first month as your body adapts.
Can I take orforglipron with food, or does it need an empty stomach?
Orforglipron can be taken with or without food and at any time of day, according to the protocols. This flexibility is a key advantage over some other GLP-1 formulations. You don't need to plan around meals for administration.
Is orforglipron safe if I have a family history of thyroid cancer?
No. Orforglipron is contraindicated if you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Like other GLP-1 agonists, there's a theoretical risk of thyroid C-cell tumors. Discuss your family history thoroughly with your healthcare provider before starting.
References
- ATTAIN-1 Phase 3 Trial (Obesity)(2025)
3,127 adults; 72 weeks. 36mg dose achieved 12.4% weight loss (27.3 lbs) versus 2.1% placebo. First oral small-molecule GLP-1 completing Phase 3.
- ATTAIN-2 Phase 3 Trial (Obesity + Type 2 Diabetes)(2025)
1,613 adults; 72 weeks. 36mg dose achieved 10.5% weight loss with 72.8% achieving ≥5% weight loss.
- ACHIEVE-1 Phase 3 Trial (Type 2 Diabetes)(2025)
559 adults; 40 weeks. All doses significantly reduced HbA1c by 1.3-1.6%; 76.2% achieved HbA1c <7%.
- Phase 2 Obesity Study(2023)
272 adults; 36 weeks. Achieved up to 14.7% mean weight reduction at 36 weeks with 45mg dose.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.